Pronto Diagnostics

The Israeli molecular diagnostics company will use artificial intelligence and phenotypic analysis to increase the diagnostic rate of its genetic tests.

By Molika Ashford
In the hunt for the genetic causes of hearing loss in local populations, researchers at Tel Aviv University have taken up targeted genomic capture and deep sequencing to root out causative mutations.

Pronto will begin offering the test to the private payor market and begin the regulatory process to make the test available to the publicly funded Israeli HMO market.

Signal Genetics' CEO J said the deal "represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology."

Starting in November, Pronto Diagnostics plans to begin marketing in Israel Epigenomics' Septin 9-based test for early detection of colorectal cancer

Pronto, based in Tel Aviv, is the first distributor for Epi proColon outside of Germany, where Epigenomics is headquartered.

Pronto will begin marketing Epigenomics' Epi proColon test in November.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.